Journal of diabetes investigation · 2025
Retrospective analysis of influences of sacubitril/valsartan in patients with diabetes with poorly controlled blood pressure in Japan.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ito Shun, Kobayashi Kazuo, Sotozawa Mari, Chiba Kyoji, Chin Keiichi, Shimura Hideo, Tsuge Toshinao, Sakai Hiroyuki, Furuki Takayuki, Matsuzaki Atsushi, Nakajima Shinichi, Takada Nobukazu, Yamamoto Hareaki, Takeda Hiroshi, Wakui Hiromichi, Iwasawa Takamasa, Aoyama Togo, Tamura Kouichi, Toyoda Masao, Kanamori Akira
Аннотация
AIMS: Achieving optimal blood pressure control remains challenging, particularly for patients with diabetes. This post-hoc study compared the efficacy and safety of switching to sacubitril/valsartan vs adding thiazide diuretics in this population.
METHODS: This retrospective study included patients with diabetes and inadequate blood pressure control in the office or home settings despite combination therapy with renin-angiotensin system inhibitors and calcium channel blockers. Patients were categorized into those receiving an additional thiazide diuretic (THZ group, n = 136) and those switching to sacubitril/valsartan (SacVal group, n = 199). The treatment effects over 12 months were analyzed using propensity score analysis with inverse probability weighting. Treatment discontinuation rates were assessed using the Cox proportional hazards model.
RESULTS: In the propensity score analysis model, target pressure achievement rates were similar between the two groups. However, compared to the THZ group, the SacVal group exhibited significantly lower uric acid levels (P < 0.001), improved glycated hemoglobin A1c (P = 0.02), and a smaller estimated glomerular filtration rate decline (P = 0.02). Treatment discontinuation due to adverse events was significantly higher in the THZ group (13% vs 1%), with a hazard ratio of 11.53 (95% confidence interval: 2.66-49.93, P < 0.001).
CONCLUSIONS: The combination of sacubitril/valsartan with calcium channel blockers provided a similar reduction in blood pressure compared with thiazide with renin-angiotensin system inhibitors and calcium channel blockers, and reported more favorable changes in uric acid levels, glycated hemoglobin A1c, and estimated glomerular filtration rate, along with a significantly better treatment tolerability.
METHODS: This retrospective study included patients with diabetes and inadequate blood pressure control in the office or home settings despite combination therapy with renin-angiotensin system inhibitors and calcium channel blockers. Patients were categorized into those receiving an additional thiazide diuretic (THZ group, n = 136) and those switching to sacubitril/valsartan (SacVal group, n = 199). The treatment effects over 12 months were analyzed using propensity score analysis with inverse probability weighting. Treatment discontinuation rates were assessed using the Cox proportional hazards model.
RESULTS: In the propensity score analysis model, target pressure achievement rates were similar between the two groups. However, compared to the THZ group, the SacVal group exhibited significantly lower uric acid levels (P < 0.001), improved glycated hemoglobin A1c (P = 0.02), and a smaller estimated glomerular filtration rate decline (P = 0.02). Treatment discontinuation due to adverse events was significantly higher in the THZ group (13% vs 1%), with a hazard ratio of 11.53 (95% confidence interval: 2.66-49.93, P < 0.001).
CONCLUSIONS: The combination of sacubitril/valsartan with calcium channel blockers provided a similar reduction in blood pressure compared with thiazide with renin-angiotensin system inhibitors and calcium channel blockers, and reported more favorable changes in uric acid levels, glycated hemoglobin A1c, and estimated glomerular filtration rate, along with a significantly better treatment tolerability.